Browsing tag:

HIV virus


As an efficacious treatment for the HIV virus, the NRTI Lamivudine is now showing promise as a drug to combat age-related macular degeneration, known also as AMD. Nucleoside reverse transcriptase inhibitors, or NRTIs are the most commonly used class of anti-HIV medications and they are touted to successfully act on the enzyme reverse transcriptase, prohibiting[…]

Read More

December 1, 2014 marked World AIDS Day, with roughly 40 million deaths worldwide over the past three decades attributed to this virulent disease. While there is no known cure for AIDS the advent of multiple drug regimens has made the treatment of the HIV virus which causes AIDS manageable for many patients globally. Unfortunately there[…]

Read More

Midstage trial data of a Pyrazinamide cocktail to treat TB has offered encouraging news for patients with the HIV infection. Coined PaMZ, this drug trio includes Pyrazinamide and two antibacterial drugs, with results going into the Phase III trial looking promising. The antibacterial drugs are PA-824, which was initially developed by the Novartis and the[…]

Read More

As an antiviral medication used to treat cytomegalovirus retinitis, also known as CMV in patients infected with the HIV virus, the current Cidofovir shortage is alarming (see the FDA Cidofovir shortage posting). Administered as an injectable treatment intravenously, the dosing of Cidofovir can take up to six hours to complete. The treatment of 75 mg/ml[…]

Read More

On August 12, 2013 Viiv Healthcare proudly announced the FDA approval of the integrase inhibitor, Dolutegravir to combat the HIV virus. Known as the brand name Tivicay, Dolutegravir is typically used in combination with other antiretroviral medications to treat patients with AIDS, ages twelve and older. With many patients living longer while being infected with[…]

Read More

As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]

Read More

On March 6, 2013 The Physician’s Weekly reported that a new Tenofovir Pro-Drug had less potential for bone and kidney toxicity, but still remained efficacious as a treatment for both Hepatitis and HIV infection. The findings were revealed at the 20th Conference on Retroviruses and Opportunistic Infections 2013 in Atlanta, Georgia. Tenofovir is a vastly[…]

Read More

The recent headlines proclaiming a cure for a Mississippi baby who had been exposed to the HIV virus which causes AIDS have captivated the world. This child was born to an HIV positive mother who had not received any prenatal care to reduce the transmission of the virus. Dr. Hannah Gay, who treated the baby,[…]

Read More

Lamivudine is also known as Epvir. Marketed by GlaxoSmithKline, the patent for Epvir is due to expire on May 18, 2016. Lamivudine is an antiviral medication that prevents human immunodeficiency virus (HIV) or hepatitis B (HBV) virus cells from multiplying in the body. This medication will treat HIV and HBV, but it is not a[…]

Read More

AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic[…]

Read More